Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children

Giorgio Gatti, G. Castelli-Gattinara, M. Cruciani, S. Bernardi, C. R. De Pascalis, E. Pontali, L. Papa, F. Miletich, D. Bassetti

Research output: Contribution to journalArticle

Abstract

We studied the pharmacokinetics and pharmacodynamics of nelfinavir administered 2 or 3 times per day to human immunodeficiency virus type 1 (HIV-1)-infected children receiving highly active antiretroviral therapy containing nelfinavir. The geometric mean trough concentrations of nelfinavir for the thrice- and twice-daily regimens were 1.55 mg/L and 1.11 mg/L, respectively (P = not significant). Nelfinavir concentrations did not correlate with total daily dose, dose per kilogram of weight, age, weight, previous protease inhibitor (PI) experience, or CD4+ cell percentage. In the 25 PI-naive children, the virus load reductions at 24 weeks of treatment with the twice- and thrice-daily regimens were comparable. A significantly higher percentage of children in the twice-daily group had a trough concentration of nelfinavir of less than the inhibitory concentration of 95% (P = .042). The decrease in the virus load at 24 weeks of treatment was not correlated with the trough concentration of nelfinavir. The variability of trough concentrations was extremely high, particularly among recipients of the twice-daily regimen, resulting in a higher number of patients with subinhibitory concentrations of nelfinavir in this group.

Original languageEnglish
Pages (from-to)1476-1482
Number of pages7
JournalClinical Infectious Diseases
Volume36
Issue number11
DOIs
Publication statusPublished - Jun 1 2003

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children'. Together they form a unique fingerprint.

  • Cite this

    Gatti, G., Castelli-Gattinara, G., Cruciani, M., Bernardi, S., De Pascalis, C. R., Pontali, E., Papa, L., Miletich, F., & Bassetti, D. (2003). Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clinical Infectious Diseases, 36(11), 1476-1482. https://doi.org/10.1086/375062